Improvement of insulin sensitivity by adding on glimepiride in type 2 diabetes patients poorly controlled with sub-maximal insulin dose
10.3760/cma.j.issn.1000-6699.2010.12.005
- VernacularTitle:加用格列美脲改善次大剂量胰岛素控制不佳的2型糖尿病胰岛素的敏感性
- Author:
Qiumei ZHANG
;
Demin YU
;
Jinjin LI
;
Jianying SHI
;
Jingyun ZHANG
;
Chunjun LI
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Glimepiride;
Insulin sensitivity
- From:
Chinese Journal of Endocrinology and Metabolism
2010;26(12):1031-1034
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of adding on glimepiride in treating type 2 diabetic patients who had suffered the disease for more than 10 years and were poorly controlled with insulin combined with nonsulfonylureas drugs. Methods Seventy-five type 2 diabetic patients poorly controlled with insulin combined with non-sulfonylureas drugs were randomly divided into glimepiride-added group (INS+GM, n = 39 )and continuation of insulin group ( INS, n = 35 ). HbA1c, plasma glucose, daily insulin dose, number of hypoglycemic events, body weight, plasma lipid concentration,and high-sensitive C-reactive protein (hs-CRP)were recorded at weeks 0, 12,and 24. The levels of plasma free fatty acid ( FFA), adiponectin, and tumor necrosis factor-α ( TNF-α ) were measured before and 24 weeks after the therapy. Results At 12 and 24 weeks, fasting blood glucose, 2 h postprandial blood glucose,and HbA1c were improved in INS+GM group more markedly than in INS group, and daily insulin dose and body weight were decreased in INS+GM compared with INS ( P＜0. 05 ). The number of hypoglycemic events and plasma lipid concentration did not differ between two groups ( P＜0.05 ). The levels of plasma FFA,TNF-α,hs-CRP, and HOMA-IR were lower in INS+GM than INS ( P＜0.05 ), the adiponectin was higher in INS + GM than INS ( P ＜ 0.05 ). Conclusion Adding glimepiride to insulin therapy resulted in a sustained better glycemic control with less insulin daily dose, decresed body weight, and no increase in hypoglycemic events as compared with the continuing insulin therapy group. Increased adiponectin, as well as decreased plasma FFA and TNF-α may underlie the improvement of insulin resistance with glimepiride treatment.
